BACKGROUND: Constitutive activation of kit contributes to pathogenesis of acute myeloid leukemia (AML) and targeting Kit may be of therapeutic benefit. APcK110, a novel inhibitor of Kit, has potent proapoptotic and antiproliferative activity in AML cell lines and primary AML samples. Here we extend our studies to the activity of APcK110 in a xenograft mouse model. METHODS: After sub-lethal whole body radiation, OCI/AML3 cells were injected intravenously in NOD-SCID mice. Ten days later, either APcK110 or phosphate buffered saline (PBS) was injected intraperitoneally every other day. Kaplan-Meier estimates were used to calculate survival. RESULTS: We show that 1) all mice injected with OCI/AML3 cells developed a clinical and histological picture consistent with myelomonocytic AML; and 2) survival of APcK110-treated mice was significantly longer compared with mice injected with PBS (p = .02). CONCLUSIONS: APcK110 is a novel kit kinase inhibitor with anti-AML activity in vitro and in vivo. Further evaluation in toxicology and clinical studies is warranted.
BACKGROUND: Constitutive activation of kit contributes to pathogenesis of acute myeloid leukemia (AML) and targeting Kit may be of therapeutic benefit. APcK110, a novel inhibitor of Kit, has potent proapoptotic and antiproliferative activity in AML cell lines and primary AML samples. Here we extend our studies to the activity of APcK110 in a xenograft mouse model. METHODS: After sub-lethal whole body radiation, OCI/AML3 cells were injected intravenously in NOD-SCIDmice. Ten days later, either APcK110 or phosphate buffered saline (PBS) was injected intraperitoneally every other day. Kaplan-Meier estimates were used to calculate survival. RESULTS: We show that 1) all mice injected with OCI/AML3 cells developed a clinical and histological picture consistent with myelomonocytic AML; and 2) survival of APcK110-treated mice was significantly longer compared with mice injected with PBS (p = .02). CONCLUSIONS:APcK110 is a novel kit kinase inhibitor with anti-AML activity in vitro and in vivo. Further evaluation in toxicology and clinical studies is warranted.
Authors: S Schwartz; A Heinecke; M Zimmermann; U Creutzig; C Schoch; J Harbott; C Fonatsch; H Löffler; T Büchner; W D Ludwig; E Thiel Journal: Leuk Lymphoma Date: 1999-06
Authors: Peter Paschka; Guido Marcucci; Amy S Ruppert; Krzysztof Mrózek; Hankui Chen; Rick A Kittles; Tamara Vukosavljevic; Danilo Perrotti; James W Vardiman; Andrew J Carroll; Jonathan E Kolitz; Richard A Larson; Clara D Bloomfield Journal: J Clin Oncol Date: 2006-08-20 Impact factor: 44.544
Authors: Sergej Konoplev; Xuelin Huang; Harry A Drabkin; Hartmut Koeppen; Dan Jones; Hagop M Kantarjian; Guillermo Garcia-Manero; Weina Chen; L Jeffrey Medeiros; Carlos E Bueso-Ramos Journal: Cancer Date: 2009-10-15 Impact factor: 6.860
Authors: Mark B Leick; Harrison Silva; Irene Scarfò; Rebecca Larson; Bryan D Choi; Amanda A Bouffard; Kathleen Gallagher; Andrea Schmidts; Stefanie R Bailey; Michael C Kann; Max Jan; Marc Wehrli; Korneel Grauwet; Nora Horick; Matthew J Frigault; Marcela V Maus Journal: Cancer Cell Date: 2022-04-21 Impact factor: 38.585